Compare BOF & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOF | GOSS |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.6M | 41.7M |
| IPO Year | 2023 | 2018 |
| Metric | BOF | GOSS |
|---|---|---|
| Price | $4.22 | $0.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $4.19 |
| AVG Volume (30 Days) | 109.6K | ★ 15.6M |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.33 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,184,018.00 | ★ $48,471,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $201.64 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 258.20 | N/A |
| 52 Week Low | $1.93 | $0.14 |
| 52 Week High | $4.95 | $3.87 |
| Indicator | BOF | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 64.07 | 35.94 |
| Support Level | $2.92 | $0.16 |
| Resistance Level | $4.86 | $0.36 |
| Average True Range (ATR) | 0.33 | 0.02 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 84.59 | 39.08 |
Branchout Food inc is engaged in the development, marketing, sale, and distribution of plant-based, dehydrated fruit and vegetable snacks and powders. Its products are currently manufactured for the company by contract manufacturers based in South America and North America that produce dehydrated fruit and vegetable products for the company using a new proprietary dehydration technology that it licenses from a third party. The Company's customers are located throughout the United States. Its current primary products are BranchOut Snacks, BranchOut Powders, and BranchOut Industrial Ingredients.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).